517 related articles for article (PubMed ID: 16380499)
21. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
22. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
[TBL] [Abstract][Full Text] [Related]
24. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
25. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
[TBL] [Abstract][Full Text] [Related]
26. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
27. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
[TBL] [Abstract][Full Text] [Related]
28. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Mittra S; Sangle G; Tandon R; Sharma S; Roy S; Khanna V; Gupta A; Sattigeri J; Sharma L; Priyadarsiny P; Khattar SK; Bora RS; Saini KS; Bansal VS
Br J Pharmacol; 2007 Feb; 150(4):480-7. PubMed ID: 17211457
[TBL] [Abstract][Full Text] [Related]
29. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
[TBL] [Abstract][Full Text] [Related]
30. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
31. Effect of Chinese prescription Kangen-karyu on lipid metabolism in type 2 diabetic db/db mice.
Yamabe N; Kim HY; Kang KS; Zhao Q; Matsumoto K; Yokozawa T
J Ethnopharmacol; 2010 Jun; 129(3):299-305. PubMed ID: 20363309
[TBL] [Abstract][Full Text] [Related]
32. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
33. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
34. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
35. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
[TBL] [Abstract][Full Text] [Related]
36. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
37. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Park SY; Shin HK; Lee JH; Kim CD; Lee WS; Rhim BY; Hong KW
J Pharmacol Exp Ther; 2009 May; 329(2):571-9. PubMed ID: 19221061
[TBL] [Abstract][Full Text] [Related]
38. Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation.
Wargent E; Sennitt MV; Stocker C; Mayes AE; Brown L; O'Dowd J; Wang S; Einerhand AW; Mohede I; Arch JR; Cawthorne MA
Lipids Health Dis; 2005 Jan; 4():3. PubMed ID: 15642120
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
40. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
